Researchers at the NIH have been not only at the forefront of developing an anti-HIV drug, but also managed to create a groundswell for such work though partnering with industry. This is because very few companies can fund early-stage research.

Joe Allen of IPWatchdog.com wrote in his blog post about the unsung successes of NIH in partnering with industry in various disease areas. He writes, "Twenty years later HIV had gone from a death warrant to something patients can manage because of a remarkable partnership between advocacy groups, NIH, Congress and the life science industry.  NIH took the lead in spurring the development of early HIV drugs, helping companies gain a better understanding of the disease and ways to alleviate it.  After that, companies took over.  Now they fiercely compete to develop more effective approaches."

For more information on how NIH efforts in partnering and commercialization has helped develop anti-HIV drugs, visit his blog post, http://www.ipwatchdog.com/2017/06/08/nihindustry-partnerships-matter-ask...

Readers interested in viewing the latest opportunities available for partnering and licensing should visit the NIH OTT website page https://www.ott.nih.gov/opportunities